These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36916290)

  • 1. Genetic and immune microenvironment characterization of HER2-positive gastric cancer: Their association with response to trastuzumab-based treatment.
    Kwon HJ; Park Y; Nam SK; Kang E; Kim KK; Jeong I; Kwak Y; Yoon J; Kim TY; Lee KW; Oh DY; Im SA; Kong SH; Park DJ; Lee HJ; Kim HH; Yang HK; Lee HS
    Cancer Med; 2023 May; 12(9):10371-10384. PubMed ID: 36916290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma.
    Porth I; Hirsch D; Ceribas Y; Weidner P; Weichert W; Götze TO; Perner S; Luley K; Heyer CM; de la Torre C; Hofheinz RD; Lorenzen S; Gaiser T
    Eur J Cancer; 2023 Apr; 183():119-130. PubMed ID: 36848831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of concomitant genomic alterations on treatment outcome for trastuzumab therapy in HER2-positive gastric cancer.
    Lee JY; Hong M; Kim ST; Park SH; Kang WK; Kim KM; Lee J
    Sci Rep; 2015 Mar; 5():9289. PubMed ID: 25786580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604).
    Saeki H; Oki E; Kashiwada T; Arigami T; Makiyama A; Iwatsuki M; Narita Y; Satake H; Matsuda Y; Sonoda H; Shimokawa M; Maehara Y;
    Eur J Cancer; 2018 Dec; 105():41-49. PubMed ID: 30391779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.
    Díaz-Serrano A; Angulo B; Dominguez C; Pazo-Cid R; Salud A; Jiménez-Fonseca P; Leon A; Galan MC; Alsina M; Rivera F; Plaza JC; Paz-Ares L; Lopez-Rios F; Gómez-Martín C
    Oncologist; 2018 Sep; 23(9):1092-1102. PubMed ID: 29700210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer.
    Wang Q; Zhang X; Shen E; Gao J; Cao F; Wang X; Li Y; Tian T; Wang J; Chen Z; Wang J; Shen L
    Cancer Lett; 2016 Sep; 380(1):20-30. PubMed ID: 27317872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab Inhibits Growth of HER2-Negative Gastric Cancer Cells Through Gastrin-Initialized CCKBR Signaling.
    Cui Y; Li SB; Peng XC; Wu J; Fu GH
    Dig Dis Sci; 2015 Dec; 60(12):3631-41. PubMed ID: 26173505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type.
    Xu C; Liu Y; Jiang D; Li Q; Ge X; Zhang Y; Huang J; Su J; Ji Y; Hou J; Lu S; Hou Y; Liu T
    Oncotarget; 2017 May; 8(20):33185-33196. PubMed ID: 28388541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor Heterogeneity in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Assessed by CT Texture Analysis: Association with Survival after Trastuzumab Treatment.
    Yoon SH; Kim YH; Lee YJ; Park J; Kim JW; Lee HS; Kim B
    PLoS One; 2016; 11(8):e0161278. PubMed ID: 27517841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.
    Koutras A; Lazaridis G; Koliou GA; Kouvatseas G; Christodoulou C; Pectasides D; Kotoula V; Batistatou A; Bobos M; Tsolaki E; Papadopoulou K; Pentheroudakis G; Papakostas P; Pervana S; Petraki K; Chrisafi S; Razis E; Psyrri A; Bafaloukos D; Kalogeras KT; Kalofonos HP; Fountzilas G
    PLoS One; 2018; 13(12):e0207707. PubMed ID: 30521571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer.
    Shi W; Zhang G; Ma Z; Li L; Liu M; Qin L; Yu Z; Zhao L; Liu Y; Zhang X; Qin J; Ye H; Jiang X; Zhou H; Sun H; Jiao Z
    Nat Commun; 2021 May; 12(1):2812. PubMed ID: 33990570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer.
    Yagi S; Wakatsuki T; Yamamoto N; Chin K; Takahari D; Ogura M; Ichimura T; Nakayama I; Osumi H; Shinozaki E; Suenaga M; Fujisaki J; Ishikawa Y; Yamaguchi K; Namikawa K; Horiuchi Y
    Gastric Cancer; 2019 May; 22(3):518-525. PubMed ID: 30328533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of natural killer cell activity for patients with HER2 + advanced gastric cancer treated with first-line fluoropyrimidine-platinum doublet plus trastuzumab.
    Cho H; Ryu MH; Lee HE; Kim HD; Kang YK
    Cancer Immunol Immunother; 2022 Apr; 71(4):829-838. PubMed ID: 34420059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
    Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
    BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
    World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2-positive gastric cancer.
    Hu X; Ma Z; Xu B; Li S; Yao Z; Liang B; Wang J; Liao W; Lin L; Wang C; Zheng S; Wu Q; Huang Q; Yu L; Wang F; Shi M
    Cancer Commun (Lond); 2023 Aug; 43(8):909-937. PubMed ID: 37434399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late stage gastric cancer patients with extra gained HER2 positivity by dual block assessment may not show compromised efficacy to trastuzumab treatment.
    Xu C; Liu Y; Jiang D; Ge X; Huang J; Su J; Zhang X; Lu S; Ji Y; Hou J; Liu T; Hou Y
    Aging (Albany NY); 2019 Nov; 11(22):10052-10060. PubMed ID: 31739285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment.
    An E; Ock CY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Liao WL; Cecchi F; Blackler A; Thyparambil S; Kim WH; Burrows J; Hembrough T; Catenacci DVT; Oh DY; Bang YJ
    Ann Oncol; 2017 Jan; 28(1):110-115. PubMed ID: 27687309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of circulating tumor cells in the response to trastuzumab for HER2-negative metastatic gastric cancer.
    Matsushita D; Uenosono Y; Arigami T; Yanagita S; Okubo K; Kijima T; Miyazono F; Hamanoue M; Hokita S; Nakashima S; Ohtsuka T; Natsugoe S
    Cancer Chemother Pharmacol; 2021 Jun; 87(6):789-797. PubMed ID: 33641065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229).
    Chia S; Bedard PL; Hilton J; Amir E; Gelmon K; Goodwin R; Villa D; Cabanero M; Tu D; Tsao M; Seymour L
    Oncologist; 2019 Nov; 24(11):1439-1445. PubMed ID: 31420468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.